In a study by Gong et al., two types of stably expressed sPD-L1 (PD-L1v242 and PD-L1v229-transmembrane domain–deficient) were identified in four patients experiencing NSCLC recurrence after anti-PD-L1 treatment. The gene discussed is SPDL1; the disease is non-small cell lung carcinoma.